182 related articles for article (PubMed ID: 15126676)
1. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
Le Gall F; Reusch U; Little M; Kipriyanov SM
Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
[TBL] [Abstract][Full Text] [Related]
2. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
3. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
5. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
6. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
7. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.
Arndt MA; Krauss J; Rybak SM
FEBS Lett; 2004 Dec; 578(3):257-61. PubMed ID: 15589829
[TBL] [Abstract][Full Text] [Related]
8. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
9. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
10. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
[TBL] [Abstract][Full Text] [Related]
11. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
12. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
13. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
[TBL] [Abstract][Full Text] [Related]
14. Efficient production of single-chain Fv antibody possessing rare codon linkers in fed-batch fermentation.
Kumada Y; Sakan Y; Kajihara H; Kihara M; Kikuchi Y; Yamaji H; Seong GH; Katoh S
J Biosci Bioeng; 2009 Jan; 107(1):73-7. PubMed ID: 19147114
[TBL] [Abstract][Full Text] [Related]
15. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
Shan D; Press OW; Tsu TT; Hayden MS; Ledbetter JA
J Immunol; 1999 Jun; 162(11):6589-95. PubMed ID: 10352275
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.
Brinkmann U; Di Carlo A; Vasmatzis G; Kurochkina N; Beers R; Lee B; Pastan I
J Mol Biol; 1997 Apr; 268(1):107-17. PubMed ID: 9149145
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.
Santos AD; Kashmiri SV; Hand PH; Schlom J; Padlan EA
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3118s-3123s. PubMed ID: 10541352
[TBL] [Abstract][Full Text] [Related]
18. Expression and functional analysis of recombinant scFv and diabody fragments with specificity for human RhD.
Asvadi P; Fletcher A; Raison RL
J Mol Recognit; 2002; 15(5):321-30. PubMed ID: 12447910
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
20. Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy.
Lee YC; Boehm MK; Chester KA; Begent RH; Perkins SJ
J Mol Biol; 2002 Jun; 320(1):107-27. PubMed ID: 12079338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
